epinastine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihistaminics 1027 80012-43-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alesion
  • epinastine
  • (+/-)-Epinastine
  • epinastine hydrochloride
  • epinastine HCl
direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell, indicated for the prevention of itching associated with allergic conjunctivitis
  • Molecular weight: 249.32
  • Formula: C16H15N3
  • CLOGP: 2.15
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 41.62
  • ALOGS: -3.18
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.15 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 2003 FDA ALLERGAN
Sept. 20, 2019 PMDA Santen Pharmaceutical Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 169.97 21.70 80 1805 93007 46591170
Hepatic function abnormal 51.70 21.70 26 1859 34395 46649782
Drug eruption 28.78 21.70 15 1870 21314 46662863
Platelet count decreased 26.59 21.70 26 1859 99998 46584179
Enzyme level abnormal 22.40 21.70 4 1881 131 46684046
Interstitial lung disease 22.26 21.70 18 1867 53931 46630246

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 85.64 25.36 46 1971 41899 29908562
Treatment failure 85.01 25.36 43 1974 34636 29915825
Interstitial lung disease 40.46 25.36 33 1984 60164 29890297
Drug eruption 35.06 25.36 19 1998 17507 29932954
Neutrophil count decreased 30.03 25.36 24 1993 42430 29908031
Pyrexia 27.80 25.36 61 1956 294428 29656033
Liver disorder 25.83 25.36 19 1998 29703 29920758

Pharmacologic Action:

SourceCodeDescription
ATC R06AX24 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
ATC S01GX10 SENSORY ORGANS
OPHTHALMOLOGICALS
DECONGESTANTS AND ANTIALLERGICS
Other antiallergics
FDA MoA N0000000122 Adrenergic Agonists
FDA MoA N0000000190 Histamine H1 Receptor Antagonists
FDA EPC N0000175519 Histamine-1 Receptor Inhibitor
FDA PE N0000175628 Decreased Histamine Release
FDA EPC N0000175883 Adrenergic Receptor Agonist
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:37955 h1-receptor blockers
CHEBI has role CHEBI:37956 histamine receptor blocker
CHEBI has role CHEBI:50857 anti-allergic agents
CHEBI has role CHEBI:66981 ophthalmologicals

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Allergic conjunctivitis indication 473460002 DOID:11204
Ocular Itching indication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.94 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 8.90 WOMBAT-PK CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 4.53 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.96 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 5.37 CHEMBL
Multidrug resistance protein 1 Transporter WOMBAT-PK
Alpha-1A adrenergic receptor GPCR WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR WOMBAT-PK
Alpha-2A adrenergic receptor GPCR WOMBAT-PK
Histamine H2 receptor GPCR WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4 WOMBAT-PK
Histamine H1 receptor GPCR IC50 8.80 CHEMBL

External reference:

IDSource
4021466 VUID
N0000148850 NUI
D01713 KEGG_DRUG
108929-04-0 SECONDARY_CAS_RN
4021466 VANDF
C0772294 UMLSCUI
CHEBI:51032 CHEBI
3241 PUBCHEM_CID
CHEMBL1106 ChEMBL_ID
CHEMBL1200491 ChEMBL_ID
DB00751 DRUGBANK_ID
C053090 MESH_SUPPLEMENTAL_RECORD_UI
7176 IUPHAR_LIGAND_ID
5953 INN_ID
Q13WX941EF UNII
236961 RXNORM
17645 MMSL
181234 MMSL
007311 NDDF
007312 NDDF
407068009 SNOMEDCT_US
407069001 SNOMEDCT_US
427671005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ELESTAT HUMAN PRESCRIPTION DRUG LABEL 1 0023-9201 SOLUTION/ DROPS 0.50 mg OPHTHALMIC NDA 21 sections
Epinastine Human Prescription Drug Label 1 17478-911 SOLUTION/ DROPS 0.50 mg OPHTHALMIC ANDA 22 sections
Epinastine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51991-836 SOLUTION/ DROPS 0.50 mg OPHTHALMIC ANDA 26 sections
EPINULLSTINE HYDROCHLORIDE Human Prescription Drug Label 1 62756-329 SOLUTION 0.50 mg OPHTHALMIC ANDA 22 sections
EPINULLSTINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 70069-008 SOLUTION/ DROPS 0.50 mg OPHTHALMIC ANDA 20 sections